Share on

In this week’s video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to IMiDs, proteasome inhibitors, and daratumumab.

BOTTOM LINE:
Selinexor will likely be approved by the FDA, demonstrating its safety and efficacy in combination with other myeloma therapies.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
If you have myeloma, should you undergo tests for DNA sequencing?
Next Post
New Guidelines for Superior Imaging, a Possible Cause of Post-Transplant Relapse, and the Future of Genetic Therapy: Myeloma News in Brief

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.